Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07464314 · ClinicalTrials.gov registry record · Phase 1
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
NCT07464314 is a Phase 1 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 225 participants.
The verdict
NCT07464314, a Phase 1 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
Study Summary
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
Interventions
- BIOLOGICAL Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- BIOLOGICAL Licensed Seasonal Influenza Vaccine
- BIOLOGICAL Licensed COVID-19 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2027-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07464314
The ClinicalTrials.gov registry entry for NCT07464314 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine is the first listed.
NCT07464314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07464314 about?
NCT07464314 is a clinical study titled "A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults". This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The st...
What is the current status of trial NCT07464314?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2026-03-09. Estimated completion is 2027-06-03.
What interventions are being tested in trial NCT07464314?
The interventions under investigation include: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine (BIOLOGICAL), Licensed Seasonal Influenza Vaccine (BIOLOGICAL), Licensed COVID-19 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07464314?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.